NCT05327946View on ClinicalTrials.gov

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

July 16, 2024

Study Completion Date

September 30, 2026

Conditions
Solid Tumors
Interventions
DRUG

BI 770371

BI 770371

DRUG

ezabenlimab

ezabenlimab

Trial Locations (5)

34232

Florida Cancer Specialists-Sarasota-61670, Sarasota

07601

John Theurer Cancer Center, Hackensack

H2X 0A9

Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal

277-8577

National Cancer Center Hospital East, Chiba, Kashiwa

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05327946 - A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated | Biotech Hunter | Biotech Hunter